LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.28 -2.65

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.21

Massimo

22.1

Metriche Chiave
By Trading Economics
Entrata	-270M 3.6M
Vendite	-16M 268M
P/E Media del settore	9.819 49.052
EPS	0.02
Margine di Profitto	1.357
Dipendenti	796
EBITDA	-31M -4.6M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+47.34% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-83M 3.7B
Apertura precedente	23.93
Chiusura precedente	21.28

Notizie sul Sentiment di mercato

By Acuity

50%

153 / 344 Classifica in Healthcare

ACADIA Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 giu 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 giu 2026, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 giu 2026, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 giu 2026, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 giu 2026, 20:51 UTC

Utili

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 20:09 UTC

Discorsi di Mercato

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 giu 2026, 19:36 UTC

Discorsi di Mercato

Cattle Climbs as Crude Oil Falls -- Market Talk

9 giu 2026, 19:32 UTC

Discorsi di Mercato

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 giu 2026, 19:25 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 giu 2026, 19:00 UTC

Discorsi di Mercato

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 giu 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 giu 2026, 18:47 UTC

Discorsi di Mercato

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 giu 2026, 18:37 UTC

Discorsi di Mercato

Canada's Cooling Trade With the U.S. -- Market Talk

9 giu 2026, 18:27 UTC

Discorsi di Mercato

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 giu 2026, 17:35 UTC

Discorsi di Mercato

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 giu 2026, 17:30 UTC

Discorsi di Mercato

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 giu 2026, 16:34 UTC

Discorsi di Mercato

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 giu 2026, 15:28 UTC

Discorsi di Mercato

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 giu 2026, 15:25 UTC

Discorsi di Mercato

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Confronto tra pari

Modifica del prezzo

ACADIA Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

47.34% in crescita

Previsioni per 12 mesi

Media 32.18 USD 47.34%

Alto 38 USD

Basso 23 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

153 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.